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Abstract:  Endogenous  Cushing  syndrome  is  an  endocrine  disease  caused  by  excessive 
secretion of adrenocorticotropin hormone in approximately 80% of cases, usually by a pituitary 
corticotroph  adenoma  (Cushing  disease  [CD]).  It  is  a  heterogeneous  disorder  requiring  a 
multidisciplinary and individualized approach to patient management. The goals of treatment 
of CD include the reversal of clinical features, the normalization of biochemical changes with 
minimal  morbidity,  and  long-term  control  without  recurrence.  Generally,  the  treatment  of 
choice is the surgical removal of the pituitary tumor by transsphenoidal approach, performed 
by an experienced surgeon. Considering the high recurrence rate, other treatments should be 
considered.  Second-line  treatments  include  more  radical  surgery,  radiation  therapy,  medical 
therapy, and bilateral adrenalectomy. Drug treatment has been targeted at the hypothalamic or 
pituitary level, at the adrenal gland, and also at the glucocorticoid receptor level. Frequently, 
medical therapy is performed before surgery to reduce the complications of the procedure, 
reducing the effects of severe hypercortisolism. Commonly, in patients in whom surgery has 
failed, medical management is often essential to reduce or normalize the hypercortisolemia, and 
should be attempted before bilateral adrenalectomy is considered. Medical therapy can be also 
useful in patients with CD while waiting for pituitary radiotherapy to take effect, which can take 
up to 10 years or more. So far, results of medical treatment of CD have not been particularly 
relevant; however, newer tools promise to change this scenario. The aim of this review is to 
analyze the results and experiences with old and new medical treatments of CD and to reevaluate 
medical therapies for complications of CD and hypopituitarism in patients with cured CD.
Keywords: ketoconazole, somatostatin analogs, dopamine agonists, rosiglitazone, Cushing 
disease, glucocorticoids, hypopituitarism
Introduction
Endogenous Cushing syndrome is an endocrine disease caused by excessive secretion 
of adrenocorticotropin hormone (ACTH) in approximately 80% of cases, usually by a 
pituitary corticotroph adenoma (Cushing disease [CD]), less often by an extrapituitary 
tumor (ectopic ACTH syndrome), and very rarely by an ectopic corticotropin-releasing 
hormone – secreting tumor. ACTH-independent Cushing syndrome, accounting for 
about 20%, is due in most instances to an adrenal tumor, or more rarely, macronodular 
adrenal hyperplasia, primary pigmented nodular adrenal disease (either as isolated 
disease or as a part of Carney complex), or McCune–Albright syndrome.1,2
In CD, elevated ACTH secretion results in excess adrenal gland cortisol secretion. 
The normal cortisol feedback mechanism of the hypothalamic-pituitary-adrenal axis 
is disturbed, with loss of circadian rhythm and excess cortisol production, resulting Therapeutics and Clinical Risk Management 2010:6 submit your manuscript | www.dovepress.com
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in hypercortisolism. Clinical features of hypercortisolism 
include weight gain, severe fatigue and muscle weakness, high 
blood pressure, depression, cognitive impairment, purplish 
skin striae, easy bruising, loss of libido, diabetes, hirsutism, 
acne, and menstrual disorders. The nonspecificity and high 
prevalence of clinical symptoms in patients without the 
disorder complicate the diagnosis of Cushing syndrome and 
also the differential diagnosis between the different causes 
of hypercortisolism.1 For this reason, efficient screening and 
confirmatory procedures are essential before considering 
therapy. On the other hand, in untreated cases, morbidity and 
mortality rates are significantly elevated compared with those 
in normal subjects especially for the high cardiovascular and 
osteoporotic risk.3–8
The goals of treatment of CD include the reversal of clinical 
features, the normalization of biochemical changes with mini-
mal morbidity, and long-term control without recurrence.9
CD is caused by an ACTH-secreting tumor in the majority 
of cases, and so, optimal treatment is surgical resection by 
selective adenomectomy. In the event of failure after initial 
pituitary surgery or relapse after a period of remission, the 
second-line therapeutic options include repeated pituitary 
surgery, radiotherapy, or bilateral adrenalectomy. Finally, 
medical therapy may have a primary or adjunctive role in 
some cases. This review will focus on surgical treatment of 
CD, on therapies in case of persistent disease after transsphe-
noidal surgery (TS), and on medical management of CD.
Surgical treatment of CD
The first-line treatment of CD is the surgical removal of the 
pituitary tumor by transsphenoidal approach, performed by 
an experienced surgeon. Repeated TS may be undertaken 
if disease persists after initial surgery as soon as persistent 
disease is evident, but a delay of 4–6 weeks may be required 
to confirm the need for reoperation.9 The transsphenoidal 
microsurgery is still the most widely used technique; there 
are still less data available on outcome in entirely endoscopic 
surgery.9 However, the excellent view of the surgical field 
during endoscopic TS seems to provide an advantage in case 
of altered anatomy in repeated surgery.10
Efficacy
Remission rates in patients with microadenoma are in the 
range of 65%–90%. The recurrence rates are 5%–10% at 
5 years and 10%–20% at 10 years. In patients with mac-
roadenoma, remission rates are lower (,65% in most 
series), and recurrence also occurs sooner than in those 
with microadenoma (mean of 16 months vs 49 months).11,12 
If an adenoma cannot be located in sellar exploration, total 
or partial hypophysectomy may be indicated, but there is 
consensus that it may induce remission less often than a 
selective tumor resection.9 The rate of success is also lower 
in repeated TS than that seen after the initial surgery;9 it has 
been shown to be effective in approximately 50%–70% of 
patients in a limited number of specialized centers.13
Prognostic factors
Favorable prognostic factors for successful surgery include 
magnetic resonance imaging (MRI) detection of the microad-
enoma, a well-defined tumor that is not invading either the 
basal dura or the cavernous sinus, histological confirma-
tion of ACTH-secreting tumor, low postoperative serum 
cortisol levels, and long-lasting adrenal insufficiency after 
surgery.9,11,12,14
Safety
The most common complications of TS are diabetes insipidus, 
cerebrospinal fluid (CSF) leakage, vascular complications 
(occlusion and bleeding), and hypopituitarism. Total or par-
tial hypophysectomy is associated with higher complication 
rates than selective tumor resection.9,12,15 Particularly, CSF 
leakage has been reported to occur more frequently during 
repeated TS than during the initial TS; this could depend 
on postoperative changes such as scar tissue but also as a 
result of a more aggressive surgical procedure in a usually 
small sella with a concave diaphragm.10 The higher rates of 
hypopituitarism after repeated TS can be expected because 
additional pituitary tissue is removed, even if the risk of 
hypopituitarism seems to be lower than reported rates several 
years after radiotherapy.16
Radiotherapy
In case of persistence or relapse of the disease, radiotherapy 
could be used. Fractionated external beam radiotherapy or 
stereotactic radiosurgery (SR) achieved control of hyper-
cortisolism in approximately 50%–60% of patients within 
3–5 years.17–20 Long-term follow-up is necessary to detect 
relapse, which can occur after an initial response to both types 
of radiotherapy. To date, comparison of SR with fractionated 
radiotherapy appears difficult due to different indications 
(such as, SR should presumably be reserved for patients with 
a small tumor volume and well delineated on MRI) and dif-
ferences in length of follow-up. A recently reported21 series 
of patients with long-term follow-up (mean 96 months) after 
SR showed the following: (1) lower antisecretory efficacy of 
SR, (2) lower risk of adverse effects of SR, mainly in terms Therapeutics and Clinical Risk Management 2010:6 submit your manuscript | www.dovepress.com
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of hypopituitarism, and (3) a risk of late recurrence after SR, 
as opposed to conventional radiotherapy.
It is well documented that pituitary radiation reduces the 
risk of tumor growth (facilitated by bilateral adrenalectomy) 
but not in all patients emphasizing the need for continued 
regular monitoring by MRI studies.
The main drawbacks of both procedures are the slow 
onset of a beneficial effect, which requires effective antise-
cretory drugs during this period, the risk of hypopituitarism, 
and the potential for damage to the brain, optic apparatus or 
cranial nerves.17 The risk of second tumor formation after 
pituitary radiation is considered to be in the range of 1%–2% 
with conventional radiotherapy.22 Studies with a more pro-
longed follow-up will be necessary for defining the risk of 
second tumor after SR. The reports19,23 of development of 
cranial nerve deficit and visual loss after a second SR treat-
ment suggest caution in repeating this procedure.
Bilateral adrenalectomy
Bilateral adrenalectomy is a definitive treatment that 
provides immediate control of hypercortisolism, and the 
morbidity can be minimized by the use of endoscopic 
approaches. However, since it determines a condition of 
permanent hypoadrenalism, it requires careful education 
and evaluation of the patient relatively to the need for 
lifelong glucocorticoid and mineralocorticoid replacement 
therapy.24 Moreover, because of the risk of developing 
Nelson syndrome, a corticotroph tumor progression, MRI 
scans, and ACTH evaluation have to be performed regularly 
in adrenalectomized patients.25
The second-line treatment for persistent hypercorti-
solism should be individualized but, generally, bilateral 
adrenalectomy may be indicated in patients with persistent 
hypercortisolism despite medical therapy or with intolerance 
to pharmacological agents or as an alternative to long-term 
medical treatment after pituitary radiotherapy and finally in 
women who wish to maintain fertility.9
Medical management of CD
At odds to other pituitary adenomas such as prolactinomas26 
or growth hormone (GH)-secreting adenomas27 in which 
medical treatment has historically or more recently gained 
a significant space, in CD, medical treatment is tradition-
ally thought to have a marginal role. Nevertheless, there 
are numerous circumstances in which medical treatment of 
CD may be indicated. In fact, medical therapy is performed 
frequently before surgery to reduce the anesthesiological risk 
of the procedure, controlling the metabolic effects of severe 
hypercortisolism in analogy to what is done in the patients 
with acromegaly.28 Moreover, in patients in whom surgery 
has failed to control the disease, medical management is 
often essential to reduce or normalize hypercortisolemia, 
and should be performed before considering bilateral adrena-
lectomy. Medical therapy can also be useful in patients 
with CD while waiting for the complete effect of pituitary 
radiotherapy (that may take up to 10 years or even more). 
Finally, it is helpful as a palliative modality in rare CD 
patients with metastatic disease that is more common with 
cortisol-secreting adrenal cancer.29
Several drugs may affect adrenal function. They can be 
schematically divided into two types: adrenolytic agents 
and neuromodulatory agents (Tables 1 and 2). Of these, the 
former are still the most successful and therefore widely 
used, whereas the latter agents are currently undergoing 
active research.
Adrenolytic agents
Ketoconazole
Ketoconazole is an imidazole derivative, which was originally 
developed as an oral antifungal agent. It is an inhibitor of 
sex-steroid and cortisol production by its action on C17–20 
lyase and 11betahydroxylase, respectively. It also inhibits 
17-hydroxylase and 18-hydroxylase activities.30 Treatment is 
usually started at a dose of 200 mg twice daily, which may be 
increased up to 1,200 mg/d in four divided daily doses.31–33
Efficacy
The clinical signs and symptoms of hypercortisolism, includ-
ing hypertension, hypokalemia, and diabetes mellitus are 
rapidly reversed, so antihypertensive and hypoglycemic drugs 
can often be discontinued. A meta-analysis of eight trials, 
involving different series of patients with CD treated with 
ketoconazole (dose range 400–1,200 mg daily), reported an 
average remission rate of 70% (range, 25%–93%).34
Side effects
Reversible elevation of hepatic serum transaminases occurs 
in approximately 5%–10% of patients, with incidence of 
serious hepatic injury in approximately 1 of 15,000 cases. 
Histological changes can vary from predominantly cholesta-
sis to extensive hepatocellular necrosis. Other adverse effects 
include skin rashes and gastrointestinal upset, and one must 
always be aware of the possibility to cause adrenal insufficien-
cy.35 Owing to its sex-steroid inhibitory action, ketoconazole 
is particularly useful in women with hirsutism, which may be 
worsened by metyrapone. On the other hand, gynecomastia Therapeutics and Clinical Risk Management 2010:6 submit your manuscript | www.dovepress.com
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and reduced libido in men may be unacceptable. One further 
potential advantage is its inhibition of cholesterol synthesis 
described in a series of patients with Cushing syndrome.33
Metyrapone
Metyrapone inhibits the enzyme 11β-hydroxylase by blocking 
the production of cortisol from 11-deoxycortisol in the adrenal 
gland. The resultant relative decrease in cortisol may stimulate 
further ACTH secretion, increasing adrenal androgen and 
aldosterone precursors with weak mineralocorticoid activity. 
The drug is often started at thrice-daily doses of 250 mg, with 
titration up to a maximum of 6 g/d.
Efficacy
The inhibitory effect of metyrapone overcomes the increased 
drive to produce cortisol and has shown efficacy over an 
extended period of treatment.36 In a large study37 including 
53 patients with CD, a short-term control of mean serum 
Table 1 Drugs with adrenolytic properties used in treatment of CD
Agent Doses Results/peculiar effects Side effects/limits
Metyrapone 750–6,000 mg/daily effective Hypoadrenalism, nausea, abdominal pain,  
hirsutism, acne 
No longer available in United  
States/compassionate use in europe
Ketoconazole 400–1,200 mg/daily effective 
Slow onset of action
Gastrointestinal upset, rashes, elevation of  
hepatic serum transaminases, gynecomastia,  
reduced libido in men
Aminoglutethimide 250 mg/2–3 times daily Less efficient in CD compared with  
the other causes of CS, often used  
as an adjunct to metyrapone
Self-limited pruritic rash, nausea, somnolence,  
dizziness, blurred vision, hypothyroidism, several   
potential medication interactions 
Cholestasis and bone marrow suppression are  
rare side effects 
No longer available
Mitotane 500 mg–12 g/daily effective (commonly used in cancer) 
Gradual dose titration, taken during  
meals
Adrenal insufficiency, gastrointestinal upset,  
neurological disturbances, elevation of hepatic  
enzymes, hypercholesterolemia, hyperuricemia,  
gynecomastia, prolonged bleeding time, change  
in hormone-binding globulins, teratogenicity
etomidate effective Case reports in pediatric population
Abbreviations: CD, Cushing disease; CS, Cushing syndrome.
Table 2 Drugs centrally active (reduction of ACTH secretion) with therapeutic potential in CD
Agent Doses Results/peculiar effects Side effects/limits
Somatostatin analogs
  Octreotide 100–300 µg/daily ineffective in clinical studies Gastrointestinal discomfort,  
gall stones, hyperglycemia,  
GH deficit?
  Pasireotide 600 μg twice daily Phase 2 study shows  
promising results
Dopamine agonists
  Bromocriptine 3–30 mg/daily Poor long-term results but  
renewed interest
Nausea and postural hypotension 
Cardiac valve dysfunction?
  Cabergoline 1–7 mg/wk More efficacious than  
bromocriptine
Postural hypotension 
Cardiac valve dysfunction?
Histamine and serotonin antagonists
  Cyproheptadine 4–24 mg/daily Small series, rarely effective Sedation, weight gain
5-HT2 antagonist
  Ritanserin No sustained effects in most  
patients
PPAR-γ receptor agonists
  Rosiglitazone
  Pioglitazone
4–16 mg/daily
45 mg daily
in vitro success not  
reproduced in clinical practice
Abbreviations:  ACTH,  adrenocorticotropin  hormone;  CD,  Cushing  disease;  GH,  growth  hormone;  PPAR-γ,  peroxisome  proliferator-activated  receptor-γ;  5-HT, 
5-hydroxytryptamine.Therapeutics and Clinical Risk Management 2010:6 submit your manuscript | www.dovepress.com
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cortisol level (#400 nmol/L) was obtained in 75% of 
patients   compared with effective long-term control in 83% of 
24 patients who were given metyrapone (mean, 2,250 mg/d; 
median, 27 months) following pituitary irradiation.
Side effects
The main side effects are hirsutism, acne (which can clearly 
be problematic in women), dizziness, and gastrointestinal 
upset. Hypoadrenalism remains the most important potential 
problem, and careful monitoring of treatment and education 
of the patient is required. Hypokalemia, edema, and hyper-
tension due to raised mineralocorticoids are infrequent but 
may require cessation of therapy.32,37
Of note, metyrapone is not commercially available but 
can be provided for compassionate use by contacting the 
manufacturer directly.
Aminoglutethimide
Aminoglutethimide, which is no longer available in the 
United States and Europe, often used at a dose of 250 mg 
2–3 times daily, prevents conversion of cholesterol to preg-
nenolone. Thus, it inhibits not only cortisol production but 
also estrogen and aldosterone production.
Efficacy
In the largest published study of 66 patients with Cushing 
syndrome,38 a favorable response was seen in 14 of 33 patients 
with CD. However, aminoglutethimide seems to be less 
efficient in CD compared with the other causes of Cushing 
syndrome. This may be due to an increase in ACTH overcom-
ing the enzymatic blockade or by hepatic enzyme induction 
that increases its own metabolism leading also to tolerance 
with continued treatment and explaining some side effects.32 
Because of its limited efficacy, aminoglutethimide is now 
most often used as an adjunct to metyrapone for reducing 
the doses and, thus, the toxicity of the drug.39
Side effects
The primary side effect is a generalized, self-limited pruritic 
rash that is usually manageable with antihistamine drugs. 
Nausea, somnolence, dizziness, and blurred vision may occur. 
As the drug blocks thyroid hormone synthesis, hypothyroid-
ism is a well-known side effect. Cholestasis and bone mar-
row suppression are rare side effects. Being a strong inducer 
of several cytochrome P450 enzymes, aminoglutethimide 
may have several potential interactions with other medica-
tions. Because this medication increases the metabolism of 
dexamethasone but not that of hydrocortisone, the latter is 
often used if steroid replacement is needed.40
Mitotane
Mitotane is often started at 250–500 mg nightly with slow 
escalation of the dose up to 4–12 g/d. This drug inhib-
its 11α-hydroxylase, 18-hydroxylase, 3α-hydroxylase, 
hydroxysteroid dehydrogenase, and several cholesterol 
side-chain cleavage enzymes. At doses greater than 4 g/d, 
it has toxic effect because its metabolite binds macromol-
ecules in adrenal cortical cell mitochondria, leading to their 
destruction and cellular necrosis. Because of this property, its 
primary use is in patients with adrenocortical carcinoma.41
Efficacy
In a large historical study42 including 46 CD patients receiving 
mitotane from 4 to 12 g/d, remission occurred in 38 cases 
(83%) in 8 months. All 16 patients who received both mitotane 
and pituitary radiotherapy were controlled. In another study43 
with adjunctive radiotherapy, remission was observed in 29 
of 36 patients (81%), and in 17 patients (47%) long-term 
mitotane therapy was not necessary. In this last study, lower-
dose mitotane regimen (up to 4 g/d) was used to reducing side 
effects. These studies not only highlighted the slow onset of 
action of mitotane but also showed that the adrenolytic effect 
can persist even after the drug is stopped.
Side effects
Side effects of this medication may limit its use. In fact, with 
doses as high as those used in carcinoma, the incidence of 
adrenal insufficiency and adverse effects, particularly gastro-
intestinal upset (57%), is significant. Of note, patients who 
undergo mitotane treatment, similarly to patients submitted 
to bilateral adrenalectomy, are at risk of developing Nelson 
syndrome if they do not receive pituitary radiotherapy.36 Other 
side effects include neurological disturbances (ataxia, vertigo, 
confusion, and language impairment), elevation of hepatic 
enzymes, hypercholesterolemia, hyperuricemia, gynecomas-
tia, prolonged bleeding time, and change in hormone-binding 
globulins.32 Hypercholesterolemia responds to treatment 
with 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors.44 
Finally, the drug is contraindicated in pregnant women for 
its teratogenicity.45
etomidate
Etomidate, a commonly used short-acting intravenous 
anesthetic, is a potent inhibitor of 11α-hydroxylase and an 
inhibitor of 17α-hydroxylase.
There have been a number of case reports on the successful 
use of etomidate in controlling hypercortisolemia in seriously 
ill patients with CD even in the pediatric population.46–48Therapeutics and Clinical Risk Management 2010:6 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
510
Mancini et al
Neuromodulatory agents
As stated above, for several reasons (mechanism of action 
and side effects), adrenolytic agents are more suitable for 
short-term adjunctive treatment. Therefore, the search for 
more “pathogenetic” drugs, which thus may act on ACTH 
secretion at the pituitary adenoma level without interfer-
ing with other hormone synthesis and may even be used as 
primary treatment, is still open.
In this vein, it is worthwhile to dedicate a specific section 
of this review to neuromodulatory centrally active agents such 
as somatostatin (SS) analogs and dopamine agonists (DAs).
SS analogs
Preclinical studies: SS receptors in normal corticotroph 
cells and in vitro studies with SS analogs  
in corticotroph cell lines and adenomas
Rat pituitary corticotrophs express multiple somatostatin 
receptors (sst), including sst2 and sst5,49 but treatment of 
cultured rat corticotrophs with native SS-14 does not result 
in inhibition of ACTH release.50 However, SS-14 is able to 
decrease ACTH release when rat pituitary cells are cultured in 
glucocorticoid-free media.51 Therefore, it can be hypothesized 
that the presence of glucocorticoids reduces the inhibitory 
effects of native SS and traditional SS analogs on ACTH release 
through the down regulation of the SS binding sites.52 A num-
ber of studies have indicated that, in the murine AtT-20 cells, 
sst2 and sst5 are principally involved in the regulation of ACTH 
release. More recently, it was found that sst5-targeting agonists 
were more effective than sst2-targeting agonists in inhibiting 
ACTH release; this could depend on dexamethasone decreas-
ing sst2 but not sst5 expression. In fact, octreotide (that binds 
preferentially sst2 but only modestly sst5), but not pasireotide 
(a universal ligand with high binding affinity for sst1, sst2, 
sst3, and sst5), lost most of its ACTH-inhibiting potential with 
glucocorticoid pretreatment53 or in patients with CD in vivo.54 
Two studies55,56 investigated the effects of SS analogs in human 
corticotroph adenoma tissues; a superior ACTH inhibition by 
pasireotide as compared with octreotide55 and a dissociation in 
some adenomas between the antisecretory and antiprolifera-
tive effects of pasireotide56 were reported similar to what is 
observed in acromegaly.57,58
Efficacy in clinical studies
In clinical studies, the currently available SS analogs, 
octreotide and lanreotide, which are effective in the treatment 
of acromegaly,59 are ineffective in CD.60–62 Many authors62–65 
have found that, in Nelson syndrome, an expanding ACTH-
producing pituitary adenoma after bilateral adrenalectomy 
may respond to octreotide with reduction in circulating 
ACTH levels. This observation could be explained with the 
lack of glucocorticoid-induced down-regulation of sst2, as 
mentioned above.52
A Phase II, proof of concept, open-label, single-arm, 
multicenter study of pasireotide in CD has been recently 
published.66 Patients self-administered pasireotide 600 μg 
subcutaneously twice daily for 15 days at 9:00 am and 
9:00 pm. The selected dose was based on pharmacokinetic 
analysis. Dose adjustments were permitted for patients who 
were unable to tolerate the protocol-specified dose (150 μg 
per injection). The primary efficacy population consisted 
of 29 patients from a total of 39 patients recruited from 
10 centers. At diagnosis, urinary free cortisol (UFC) had 
to be at least two times above the upper limit of normal. 
UFC levels decreased in 76% of patients but only 17% (5 
of them) normalized UFC levels after 15 days. Overall, 
the mean UFC level decreased from baseline by 44.5%. In 
addition, reduction in serum cortisol and plasma ACTH was 
observed during the pasireotide treatment. There was a trend 
(P = 0.102) toward a lower baseline UFC level being predic-
tive of a response to pasireotide. There were no significant 
differences in baseline ACTH area under the curve (AUC0–8 h) 
values between UFC responders and nonresponders. A 1.8-
fold higher plasma concentration and 1.3-fold higher plasma 
exposure of pasireotide were observed in UFC responders 
than in nonresponders suggesting a role of pasireotide expo-
sure in determining reponse to treatment.
Safety and tolerability
The most common events with pasireotide were drug-related 
gastrointestinal disorders (54% of patients), mainly diarrhea 
(44%), nausea (23%), and abdominal pain (18%). Hypergly-
cemia, another potential effect of SS analogs,67 occurred in 
14 patients (36%) and 1 of them, with a pre-existing history 
of diabetes mellitus, discontinued the treatment. Analysis of 
insulin and glucagon levels at baseline vs during treatment 
indicated that pasireotide administration was followed by ini-
tial suppression of insulin but did not significantly influence 
glucagon release.
Another potential problem of pasireotide in CD might 
be its effects on GH and insulin-like growth factor (IGF)-1 
levels in CD. In preclinical studies, pasireotide significantly 
decreased GH and IGF-1 levels. In patients with CD, hyper-
cortisolism per se causes a relative GH deficiency (GHD),68,69 
and therefore, these patients may be at greater risk to become 
GH deficient. Future clinical studies are needed to clarify 
this aspect.Therapeutics and Clinical Risk Management 2010:6 submit your manuscript | www.dovepress.com
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Dopamine agonists
Preclinical studies: DA receptors in normal  
corticotroph cells and in vitro studies with DA  
in corticotroph adenomas
In humans, no conclusive data exist whether ACTH release is 
directly regulated by DA receptors in normal corticotroph cells.70 
On the other hand, in rats, it is known that the intermediate lobe 
in the pituitary is under tonic inhibitory control of the hypo-
thalamic dopaminergic neurons.71 In humans, the intermediate 
lobe is a rudimentary structure although it has been suggested to 
maintain some biological functions;72,73 corticotroph adenomas 
arising from the intermediate lobe may be more likely to respond 
to the classical dopaminergic agent bromocriptine.70
In 2004, Pivonello et al74 showed that the majority (80%) of 
human corticotroph adenomas express the D2 receptors as dem-
onstrated by immunohistochemistry and reverse transcriptase – 
polymerase chain reaction. Moreover, functional studies in vitro 
correlated very well with the D2 expression data, and adenomas 
with high D2 expression responded well to either bromocriptine 
or the newest dopaminergic cabergoline with acute inhibition 
of ACTH release by 43% to 60%.
Efficacy in clinical studies
Although initial reductions in ACTH levels were evident in 
almost half of patients with CD in response to bromocriptine 
administration, a sustained response occurred only in a small 
percentage of patients.70 Compared with bromocriptine, cab-
ergoline binds with even greater specificity and affinity to D2 
receptors and has a longer duration of action. In the study by 
Pivonello et al74 20 patients with CD were treated with caber-
goline at a dose of 1–3 mg/wk for 3 months with a significant 
decrease in UFC in 60% of the patients and even complete 
normalization in 40% of them. Several other case reports sug-
gested that at least in some patients with CD, cabergoline could 
control cortisol hypersecretion.75,76 More recently, Pivonello 
et al77 in the extension of a previously reported preliminary 
study, evaluated for the first time the results of chronic caber-
goline treatment in CD. The results of the study demonstrated 
that a 24-month treatment with cabergoline, at doses between 
1 and 7 mg/wk, induced or maintained control of cortisol 
secretion in 40% and induced tumor shrinkage in 20% of a 
group of 20 patients with CD, improving hypertension and 
glucose tolerance in the majority of patients, regardless of the 
normalization of cortisol secretion.
Safety and tolerability
Concerning the long-term study with cabergoline,77 no 
severe side effects were documented. However, hypotension 
associated with severe asthenia was observed in two patients, 
who stopped the drug after 12 and 18 months of treatment. A 
transient moderate asthenia was registered in four patients, 
whereas a transient mild dizziness with nausea was reported 
by another patient but these latter side effects did not require 
treatment withdrawal. It is noteworthy that no significant 
cardiac valve dysfunction was found in this study, with the 
exception of a slight worsening of tricuspid regurgitation 
in one patient. This is important because high-dose, long-
term cabergoline therapy has been recently described to be 
associated with an increased prevalence of cardiac valve 
insufficiency25,26 not only in Parkinson disease.78 However, 
because of the short period of follow-up so far available 
(maximum 2 years), no firm conclusion on this side effect 
of cabergoline in CD may be drawn.
Combined treatment with SS and DA agonists
Considering the presence of both sst and DA receptors in 
human corticotroph adenomas, the cotreatment with SS 
analogs and DA agonists (pasireotide + cabergoline) or 
perhaps, in the future, the administration of SS–DA chimeric 
compounds, such as BIM-23A760, already tested in vitro in 
GH-secreting adenomas, seem to be a reasonable approach. 
Very recently, pasireotide monotherapy has been shown to 
induce sustained normalization of the level of UFC in 5 of 17 
patients studied (29%). The addition of cabergoline normal-
ized UFC values in another 4 of 17 patients (24%). At day 
60, 8 of 17 patients (47%) still had elevated UFC levels with 
the pasireotide–cabergoline combination, although a trend 
toward normalization was observed in all except one, with a 
mean decrease of 48% ± 6% in the level of UFC.79
PPAR-γ agonists
In 2002, the nuclear hormone receptor, peroxisome 
proliferator-activated receptor-γ (PPAR-γ), was identified in 
ACTH-secreting pituitary tumors. Development of murine 
corticotroph tumors, generated by subcutaneous injection of 
ACTH-secreting AtT-20 cells, was prevented in 4 of 5 mice 
treated with the PPAR-γ receptor agonist rosiglitazone, and 
ACTH and corticosterone levels were suppressed in all 
treated mice.80
Efficacy and side effects
In a study of 10 patients, four prior to surgery, four following 
relapse after surgery, and two immediately after failed 
surgery treated with 4–16 mg of rosiglitazone for 1–8 months 
(median 3 months), and no consistent reductions in UFC 
levels were found.81Therapeutics and Clinical Risk Management 2010:6 submit your manuscript | www.dovepress.com
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Side effects reported included edema, weight gain, som-
nolence, and increased hirsutism. In a larger study, 14 patients 
with active CD (7 untreated and 7 after unsuccessful surgery) 
were treated with 8–16 mg of rosiglitazone for 1–7 months.82 
In six patients, 24-hour UFC was significantly lowered and 
two of them also noted clinical improvement at 7-month 
follow-up. Relatively, to side effects, one patient developed 
hypercholesterolemia. Although most studies used rosiglita-
zone, pioglitazone has also been tried;83 in none of five patients 
with CD treated with pioglitazone, 45 mg for 30 days, any 
UFC responses were observed. Therefore, clinical trials of 
PPAR-γ agonists in CD have lead to disappointing results, 
unfortunately, failing to reproduce the success observed in the 
in vitro and mouse model. It should be recalled that human 
corticotroph tumors have a different proliferative potential 
than murine AtT-20 cells, as the latter quickly replicate and 
grow when implanted into nude mice. Conversely, human 
pituitary ACTH-secreting tumors do not exhibit such a pro-
nounced growth pattern and indeed are typically small in size 
even in patients with long-standing CD. If the ACTH-lowering 
effect of rosiglitazone is primarily due to its antiproliferative 
effect, a long time frame would be necessary for a decrease in 
ACTH levels to occur in human pituitary tumors. Furthermore, 
rosiglitazone might be more effective in ACTH-secreting mac-
roadenomas than in microadenomas. This possibility remains 
to be investigated as none of the patients with CD included in 
clinical trials presented with macroadenoma. An additional 
consideration is that the dose of rosiglitazone used in clinical 
studies was far less than that used in mice with experimental 
CD,81 which attained 10–50 fold greater concentrations of 
the drug. Finally, a potential concern for the long-term use 
of rosiglitazone in CD is its pro-osteoporotic effects already 
observed in diabetic patients.84
Retinoic acid
The antiproliferative action and the ACTH and corticosterone 
inhibition induced by retinoic acid in vitro were confirmed 
in vivo in mice with experimental ACTH-secreting tumors and 
in dogs with CD. However, the efficacy of these treatments in 
patients with CD still needs to be tested in clinical trials.85
Glucocorticoid receptor antagonists
Finally, in analogy with acromegaly where the peripheral GH 
antagonist pegvisomant has been successfully used,26,86 an 
antagonist to block the peripheral effects of glucocorticoids 
may be engineered for the future. So far, there is no signifi-
cant experience reported with the glucocorticoid receptor 
antagonist mifepristone (RU 486) in CD, and assessment 
of its efficacy in the absence of a biochemical marker is 
challenging.9 In a European retrospective study, clinical signs 
of hypercortisolism improved rapidly in three of four patients 
with CD treated with mifepristone but one developed hyper-
tension and severe hypokalemia during the therapy.87
Therapy for the complications of CD
Cardiovascular complications
Arterial hypertension is a common feature in CD (70%–80% 
of the patients) and may be the first sign of CD. Conventional 
antihypertensive therapy (thiazides, angiotensin-converting 
enzyme inhibitors, and calcium antagonists are generally 
considered as first choice) may be only partially effective, 
whereas the additional successful use of cortisol-lowering 
agents may improve blood pressure control.88 Hypertension 
remits in most patients after successful treatment, but in 
some cases, it may persist probably because of microvessel 
remodeling and/or underlying essential hypertension.89
Epidemiological studies show that 20%–30% of patients 
with CD have diabetes mellitus, whereas impaired glucose 
tolerance is reported in 30%–60% of them.90 The impairment 
of glucose metabolism generally resolves with normaliza-
tion of cortisol levels because hypercortisolism per se is 
the causative factor of hyperglycemia. However, treatment 
with SS analogs, as previously reported, may theoretically 
cause the appearance or the worsening of diabetes.67 Diabetes 
should be controlled by oral hypoglycemic drugs or, more 
frequently, by insulin therapy.
The metabolic syndrome of CD associated with the hyper-
coagulability state determines an increased cardiovascular 
risk that may persist after cure and is the principal cause of 
death in CD patients with persistent hypercortisolism. In the 
absence of prospective randomized trials, there is general 
agreement that patients with CD should be given heparin 
during inferior petrosal sinus sampling and low-dose heparin 
treatment should be considered in the immediate periopera-
tive period.1
Osteoporosis
Several authors reported that glucocorticoid-induced osteo-
porosis is reversible.8,91 Patients with Cushing syndrome had 
a restoration of osteoblast activity, evaluated on the basis of 
increased osteocalcin levels, after 6 months of disease cure, 
without achieving any relevant changes in bone mineral den-
sity (BMD). Thereafter, remarkable improvement of BMD 
can be observed in almost all patients after a normalization 
period of cortisol levels lasting 12–36 months.92 Similarly, in 
a retrospective study of 17 patients with Cushing syndrome, Therapeutics and Clinical Risk Management 2010:6 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
513
Treatment of Cushing disease
after several years of cure, normalization of BMD at lumbar 
spine and femoral neck was reported.93
Moreover, bone impairment in patients with childhood 
and adulthood onset CD can be partly, but not completely, 
reversed 2 years after normalization of cortisol levels, sug-
gesting that longer recovery times or additive therapeutic 
approaches are necessary to maximize peak bone mass in 
children and restore bone mass in adults with CD.94
The mechanism of the recovery in BMD can only 
be speculative. Glucocorticoids rapidly and sharply increase 
bone resorption (this is considered the major contributor to the 
almost immediate increase in fracture risk caused by excess 
corticosteroid levels) but importantly, particularly in the long-
term, they diminish bone formation rate.95,96 This latter effect 
as evaluated by circulating levels of osteocalcin is rapidly 
reversible with normalization of hypercortisolism. A second 
important contribution to this recovery may be the preservation 
of trabecular architecture despite trabecular thinning in steroid-
induced osteoporosis, so the framework in which the osteoblasts 
can synthesize new bone is intact. This contrasts with the loss 
of trabeculae that occurs in other forms of osteoporosis.1
In patients treated with ketoconazole after unsuccessful 
pituitary surgery, even when normalization of cortisol levels 
was achieved, BMD remained low; this finding could be in 
line with slow and difficult recovery of bone metabolism after 
cure of CD but, alternatively, could suggest an interfering 
effect of ketoconazole on bone metabolism.97 Overall, it can 
be concluded that the recovery of bone loss is gradual, tak-
ing approximately 10 years to complete. In the meanwhile, 
patients with severe osteopenia are exposed to a high risk of 
fracture. Therefore, in these patients, the use of antiresorptive 
medications could be useful. In fact, recent data suggest that 
alendronate may induce a more rapid improvement in BMD 
than cortisol normalization alone, probably by restoring the 
balance between bone formation and resorption. In addition, 
alendronate treatment was also shown to be useful in patients 
with persistent postsurgical hypercortisolism as it prevented 
further bone loss.98
Although there are no large prospective studies in patients 
with CD, additional therapies, such as calcium and vitamin D 
supplementation and sex hormone replacement in men or 
women with hypogonadism, may likely be beneficial.1 New 
data on the use of anabolic therapies (parathyroid hormone 
and GH)99,100 in glucocorticoid-induced osteoporosis are 
encouraging and could be also perspectively applied to 
patients with endogenous hypercortisolism.101–103
Considering that the risk of fractures persists sometime 
after cure of hypercortisolism, the decision to discontinue 
antiresorptive therapy should be based at least on clinical 
monitoring and dual energy X-ray absorptiometry measure-
ments.1 However, because BMD is not a good predictor of 
fractures in CD, a spine X-ray could also be indicated.104
Hypopituitarism in cured CD
Hypopituitarism is a well-known possible complication of 
surgery and radiotherapy for pituitary diseases. As previously 
stated, several treatments of CD may induce hypopituitarism. 
However, although the necessity of substitutive treatment of 
several tropin deficiency, including ACTH, is intuitive, there 
is still, for several reasons, interest and debate surrounding 
prevalence, diagnosis, and treatment of GHD. In fact, even 
subtle excess of glucocorticoids inhibits GH secretion;105 
indeed, GH secretion is impaired in both children and adult 
patients with CD.106 In contrast, to what extent recovery of 
GH secretion follows the normalization of cortisol levels is 
less well established.107 This uncertainty is due to the fact 
that patients were often tested shortly after remission of 
hypercortisolism, and remission was achieved by several 
treatment modalities, including radiation therapy, which is 
known to progressively impair anterior pituitary function 
over time. Further, patients cured from CD frequently do not 
normalize body weight and this may confound the interpreta-
tion of GH status.108
Some studies reported the presence of GHD in a high per-
centage of CD after long-term remission of hypercortisolism 
obtained by surgery alone.109 A retrospective cross-sectional 
study110 has been recently published with the comparison 
of cured patients with CD (n = 684, 74% women) and 
nonfunctioning pituitary adenoma (NFPA; n = 2,990, 39% 
women) treated for 3 years with GH after the diagnosis of 
GHD.111,112 The study showed a significant delay in GHD 
diagnosis in the CD group, who had a higher prevalence of 
hypertension, fractures, and diabetes mellitus. In untreated 
GHD, comorbidities, including impairment of quality of life, 
were more prevalent in patients with previous CD. Overall, 
both groups responded similarly to GH replacement, sug-
gesting that patients with GHD due to CD may benefit from 
GH to the same extent as those with GHD due to NFPA. On 
the other hand, improvements in BMD occur later in patients 
with prolactinomas and CD treated with GH when compared 
with NFPA.113
Finally, when the long-term complications were 
considered, GH-treated patients with previous hypercorti-
solism showed an increased risk of metabolic syndrome, car-
diovascular disease, and cerebrovascular disease as compared 
with GH-treated patients with previous NFPA.114Therapeutics and Clinical Risk Management 2010:6 submit your manuscript | www.dovepress.com
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Conclusion
CD is a severe and complex clinical syndrome, which needs 
aggressive and possibly rapid curative treatment due to 
its long-term sequelae. Unfortunately, current therapeutic 
options do not achieve cure in a relevant part of patients even 
in the hands of the most specialized centers. Therefore, the 
search for new medical effective tools is still open, and already 
promising results have been obtained. Finally, these consider-
ations emphasize the need of a careful follow-up and aggres-
sive treatment of complications in CD particularly in patients 
with difficult control of the disease but also interestingly and 
somewhat paradoxically in patients with cured CD.
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